[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anti-obesity-agents\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anti-obesity-agents":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642092","precision-obesity-medicine-genetic-prediction-of-response-to-glp-1gip-agonists-100642092",false,"NCT07653412","Precision Obesity Medicine: Genetic Prediction of Response to GLP-1\u002FGIP Agonists.","Prediction of Response to GLP-1\u002FGIP Receptor Agonists in Obesity Using Genetic Risk Score and SNP Profiling: A Prospective Cohort Study.","Diagenix","Inclusion Criteria:\n\nAge ≥18 years BMI ≥40 kg\u002Fm² or ≥37 kg\u002Fm² with comorbidities Initiation of semaglutide or tirzepatide\n\nExclusion Criteria:\n\nPrior bariatric surgery Secondary causes of obesity Active malignancy Chronic pancreatitis Family history of medullary thyroid carcinoma","ALL","18 Years",{"count":20,"type":21},220,"ESTIMATED","6 Months","OBSERVATIONAL","Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)\u002FGLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may contribute to these differences in treatment outcomes.\n\nThe aim of this prospective cohort study is to investigate whether a Genetic Risk Score (GRS) and selected obesity-related single nucleotide polymorphisms (SNPs) can predict weight loss response to semaglutide or tirzepatide in adults with obesity. Participants initiating treatment with either medication will undergo clinical, biochemical, and genetic assessment at baseline and will be followed for six months. The study will evaluate the association between genetic markers and treatment response and develop predictive models integrating genetic and clinical variables. The findings may contribute to the development of personalized treatment strategies for obesity.",[26,27,28],"Obesity (Disorder)","Anti-obesity Agents","Precision Medicine",[30,31,28,32,33],"Obesity","Genetic Risk Score","GLP-1 Receptor Agonist","GIP\u002FGLP-1 Receptor Agonist","RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":38},"2026-04-22",{"date":42,"type":21},"2027-06-30",{"name":44,"class":45},"National and Kapodistrian University of Athens","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":46},"100560330","phase-1-physiologic-response-to-bariatric-surgery-and-the-impact-of-adjunct-semaglutide-in-adolescents-100560330","NCT06575738","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide - in Adolescents (the PRESSURE Trial)","PRESSURE","Observation Phase\n\nInclusion Criteria:\n\n* Signed and dated informed consent form\n* Willingness to comply with all study procedures and availability for the duration of the study\n* Male or female biological sex, age 12 through 24 years\n* In the preoperative pathway for vertical sleeve gastrectomy\n\nExclusion Criteria:\n\n* Planned Roux-en-Y gastric bypass\n* Hypothalamic obesity\n* Type 2 Diabetes\n* Current use of oral glucocorticoids (i.e. within 10 days of baseline visit)\n* Current use of insulin\n\nIntervention\u002FTreatment Phase\n\nInclusion Criteria:\n\n* Signed and dated informed consent form\n* Status post vertical sleeve gastrectomy\n* Male or female biological sex, age 12 through 24 years\n* Meeting minimum nutrition goals\n* Obesity: age 12-17 years: BMI ≥95th%ile for age\u002Fsex \\| age 18-24 years: BMI ≥ 30kg\u002Fm\\^2\n* If entering the Intervention phase from the Observational phase: ≤20% BMI loss at 1 year postop\n* If entering the Intervention phase from the existing patient pool: ≤20% BMI loss at 1-2 years postop\n\nExclusion Criteria:\n\n* Surgically correctable cause of suboptimal postoperative weight loss\n* Known hypersensitivity to any component of semaglutide\n* Personal or family history of medullary thyroid carcinoma\n* Personal history of multiple endocrine neoplasia type 2\n* Hypothalamic Obesity\n* Type 2 Diabetes\n* History of pancreatitis\n* Uncontrolled hypertension\n* Clinically significant arrhythmia or heart disease that could be exacerbated by increased heart rate\n* Malignant neoplasm within the last 5 years\n* Untreated thyroid disorder\n* Tanner Stage 1\n* Baseline alanine transaminase (ALT) or aspartate aminotransferase (AST) ≥ 5x upper limit of normal\n* Baseline Creatinine \\>1.2mg\u002FdL\n* Active treatment for bulimia nervosa\n* Active major psychiatric disorder limiting informed consent\n* Suicidal ideation of type 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)\n* Intentional self-harm within the previous 1 month\n* Severe unmanaged depression, defined by Center for Epidemiological Studies Depression (CESD) score of 26 or greater and by clinical evaluation\n* Recent change to concomitant medications for hypertension, dyslipidemia, depression or anxiety (\\\u003C4 weeks prior to enrollment)\n* Use of oral glucocorticoids (within 10 days of baseline visit)\n* Use of metformin (within 3 months of baseline visit)\n* Use of insulin secretagogues (within 4 half-lives of the medication of baseline visit)\n* Current use of insulin\n* Use of anti-obesity medications (within 4 half-lives of the medication of baseline visit)\n* Current pregnancy\n* For females of reproductive potential: Plan to become pregnant in the next 8 months\n* For females of reproductive potential: Not on contraception (i.e. two forms of birth control for example oral birth control pills and condoms) for at least 1 month prior to enrollment and agreement to use these during study participation and for an additional 8 weeks after the final dose of study medication","12 Years","24 Years",{"count":58,"type":21},40,"INTERVENTIONAL",[61],"PHASE1","The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide) can help people 12 to 24 years old who, between 1 and 2 years after bariatric surgery, have not lost as much weight as expected.",[30,64,65,66,67,27],"Adolescent Obesity","Body-Weight Trajectory","Weight Loss Trajectory","Bariatric Surgery",[30,69,67,70,71,72],"Anti-obesity medication","Bariatric Surgery Post Operative Outcomes","Semaglutide","Sleeve gastrectomy","2026-01-08",{"date":75,"type":38},"2026-01-12",{"date":77,"type":38},"2024-10-11",{"date":79,"type":21},"2027-10-01",{"name":81,"class":45},"University of Colorado, Denver",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":90,"minAge":18,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":94,"conditions":95,"keywords":103,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":46},"100588716","monitoring-nutritional-consequences-of-obesity-treatment-on-womens-health-100588716","NCT06945016","Monitoring Nutritional Consequences of Obesity Treatment on Women's Health","MOnitoring NUtritional COnsequences of Obesity Treatment on Women's Health and Transgenerational Effects for Healthier Future Generations: a Multicentre Prospective Observational Cohort Study","MONUCO","General Inclusion Criteria:\n\n* Female sex at birth\n* Aged 18-55 years of age\n* Living with obesity (BMI ≥ 30 kg\u002Fm2)\n* Approved for obesity treatment in one of the participating hospitals:\n* Undergoing primary bariatric surgery (RYGB, OAGB or SG)\n* Receiving obesity medication (any type) with a BMI ≥30 kg\u002Fm2 under medical supervision.\n* For those undergoing MRI, DEXA and quantitative ultrasound scan: Willing to be informed about incidental findings of pathology and approving of reporting this to their general physician.\n\nAdditional inclusion criteria for birth cohort:\n\n* Being pregnant\n* Age 18-45 years of age\n* Having received prior obesity treatment, either surgical (RYGB, OAGB, SG) or pharmacological for at least 4 months under medical supervision (any type).\n\nGeneral Exclusion Criteria:\n\n* Male sex at birth\n* Aged \\\u003C18 or \\>55 years of age\n* BMI \\\u003C30 kg\u002Fm2\n* Not able to read and\u002For write in Dutch\n* Undergoing a revisional or secondary bariatric procedure (excluding previous gastric banding)\n* Malnutrition due to other chronic condition, specifically malignancy, substance abuse\n* (mental) condition that makes it impossible to fill out a questionnaire correctly.\n* For those undergoing a DEXA scan: height \\>196 cm or weight \\>160 kg\n* For those undergoing a MRI scan: having a contra-indication to MRI scanning including (but not limited to) pacemakers and defibrillators, intraorbital or intraocular metallic fragments, ferromagnetic implans or claustrophobia.\n\nAdditional exclusion criteria birth cohort:\n\n* Aged \\\u003C18 or \\>45 years of age\n* \\>25 weeks of gestation\n* Multiple pregnancy\n* Reversal of the bariatric procedure","FEMALE","55 Years",{"count":93,"type":21},1150,"The goal of this observational study is to investigate the long-term effect of obesity treatments on the health of women. This study will specifically focusses on the effects on nutritional intake, nutritional status, musculoskeletal health and reproductive health. Additionally, this study will also investigate the effect of obesity treatment on pregnancy outcomes and child development.\n\nTo achieve the goal of this study, participants already receiving either surgical treatment for obesity or treatment with anti-obesity medication as part of their regular medical care will fill in additional questionnaires, provide blood, urine and feces samples, and undergo additional measurements of body composition and muscle strength up to for 10 years.",[96,67,27,97,98,99,100,101,102],"Obesity and Obesity-related Medical Conditions","Body Composition","Muscle Strength","Reproductive Health","Mental Health","Pregnancy","Nutritional Status",[104,105,106,107,108,109,110,111],"cohort","obesity treatment","obesity","Bariatric surgery","anti-obesity agents","body composition","nutrition","observational","2025-07-06",{"date":114,"type":38},"2025-07-10",{"date":116,"type":38},"2025-01-28",{"date":118,"type":21},"2040-01-28",{"name":120,"class":45},"Wageningen University and Research"]